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Introduction
Nonviral gene delivery using cationic liposome-based, plasmid DNA complexes (lipoplex) has demonstrated promising results in both in vivo models of genetic disease and clinical trials. A major limitation for these vectors, however, is a low gene transfer efficiency compared with viral vectors. A second generation of cationic liposome-based vectors has been developed that consists of a ternary complex of cationic liposome, polycationic polymer with DNA-condensing activity, and DNA (lipopolyplex). [1] [2] [3] These novel formulations provide improved gene transfer activity both in vitro and in vivo compared with lipoplex vectors. Recently, our laboratory has developed a lipopolyplex composed of DOTAP: cholesterol liposomes, protamine sulfate, and plasmid DNA (LPD) that provides improved gene transfer activity, compared with lipoplex, to the lung, heart, liver, kidney and spleen following tail vein injection in mice. 3 The organ showing the greatest level of gene expression is the lung. Histological analysis with ␤-galactosidase and EGFP reporter genes demonstrates that endothelial cells are the primary cells transfected in the lung. 4 It has been hypothesized that LPD might be an effective vector for gene delivery to pulmonary tumors, because the neovasculature of pulmonary metastases are derived from the lung vasculature. 4 Recently, a pro-inflammatory cytokine response to i.v. administration of LPD has been observed that affects the levels of gene expression with subsequent injections. 5, 6 It appears that plasmid DNA in the complex is responsible for triggering the cytokine response. Similar to i.v. administration of lipoplex, no specific immunity is induced against the complex since prolonging the length of time between injections (7-10 days) can retain the expression levels observed with the initial injection. It is well established that bacterial DNA can initiate a potent inflammatory cytokine response following localized injection (intramuscular, subcutaneous, intraperitoneal or intra-tumor) [7] [8] [9] [10] [11] [12] [13] or intratracheal instillation. 14, 15 It appears that unmethylated CpG sequences, occurring at higher frequency in bacterial DNA compared with vertebrate DNA, are responsible for inducing the cytokine response (reviewed by Kreig). 16 Indeed, both bacterial DNA and oligonucleotides (ODN) containing immune-stimulatory CpG motifs can directly stimulate macrophages 10, 17 and dendritic cells 18, 19 for the production of TNF-␣ and IL-12. This immune-stimulatory DNA (is-DNA) is also mitogenic to B cells and induces IL-6 and IgM secretion. 20, 21 Natural killer cell (NK) lytic activity and IFN-␥ secretion are increased following injection of bacterial DNA and appear to result from the stumulatory effect of TNF-␣ and IL-12 produced from macrophages and dendritic cells. 22, 23 Interestingly, direct or intraperitoneal injection of bacterial DNA can have antitumor effects with various subcutaneous 13, 24 and intraperitoneal 25 models of murine tumors. Because the pro-inflammatory cytokines induced by bacterial DNA can mediate antitumor responses, it is likely that these cytokines mediate the antitumor effect.
In this report LPD was assessed for its efficacy as a vector for gene therapy of lung metastasis. An experimental model of pulmonary metastasis using 24JK-FBP fibrosarcomma cells that are syngeneic in C57BL/6 mice was utilized. Similar to observations with is-DNA treatment of subcutaneous and intraperitoneal tumor models, we found a potent antitumor activity with i.v. administration of LPD that was independent of the specific 'therapeutic' gene encoded in the plasmid. In addition, i.v. administration of LPD containing noncoding DNA also inhibited the growth of a subcutaneous model of C3 fibrosarcoma. This novel antimetastatic activity of LPD was further characterized with respect to the role of immune-stimulatory CpG motifs in the plasmid DNA component and the resulting Th1-like cytokine response to is-DNA. Based on the results, it is speculated that i.v. administration of LPD might serve as an effective adjuvant for DNA vaccination in the treatment of metastatic cancer.
Results

LPD possess a potent antitumor activity
In order to determine the efficacy of LPD as a vector for gene therapy of pulmonary metastasis, two strategies of gene therapy were assessed in an experimental model of pulmonary metastasis (Figure 1 ). The first strategy was an immune therapy with the antitumor cytokine IL-12 (pCMV-IL-12), and the second strategy was a tumor suppressor therapy with p53 (pCMV-p53). The data in Figure  1 represent compilation of four different experiments. Control plasmids included pEGFP to control for transgene expression and the empty vector control pCMVNeo, ie the empty vector for pCMV-p53. Three different doses of plasmid DNA were administered by tail vein injection as a component of LPD following the regimen described in Materials and methods. Each group of mice received three injections spaced 10 days apart with the first injection occurring within 1 week following tumor inoculation. All doses of LPD regardless of the plasmid provided a significant antitumor effect compared with dextrose-treated controls (P Ͻ 0.001 for all plasmids and doses, except for the 6.25 g dose of IL-12 plasmid P Ͻ 0.05). Indeed, the antitumor effect was so potent, that there was no significant difference between LPD formulated with control plasmids and those formulated with therapeutic plasmids at all doses tested. The per cent inhibition of tumor burden was 50-65% at a dose of 6.25 g, 65-75% at a dose of 12.5 g, and 75-87% at a dose of 25 g, demonstrating a dose-dependent response. To assess for the possibility that endotoxin contamination of plasmid DNA is responsible for the antitumor activity, all plasmid DNA preparations used in the LPD formu- lations were assessed for endotoxin levels by the chromogenic lymulus amebocyte lysate assay. Even at the highest dose of LPD there was no significant difference between LPDs prepared with highly contaminated plasmid DNA (pEGFP -44 EU/g DNA and pIL-12 -30 EU/g) and plasmid DNA with no contamination (pCMV-Neo and pCMV-p53 -Ͻ0.01 EU/g). Furthermore, the antitumor effect is not a result of any individual component or associated contaminant, since treatment with corresponding doses of individual LPD components has no effect on tumor burden (data not shown).
In addition, LPD treatment using noncoding plasmids also inhibited the growth of a subcutaneous model of C3 fibrosarcomma in C57BL/6 mice (P Ͻ 0.01 for pCMVNeo and P Ͻ 0.025 for pNGVL-1) in three different experiments ( Figure 6 ). The level of inhibition was essentially the same (50%) regardless of the plasmid utilized. Therefore, the antitumor effect appears to be systemic since LPD inhibited the growth of C3 tumors residing at a site distant from where LPD is known to distribute following i.v. injection. Although the level of inhibition was less than that observed with pulmonary metastases, inhibition in both tumor model systems indicates that the effect may be broadly specific to a variety of tumor models. Together, these data suggest that LPD possess a potent antitumor activity that is dose-dependent, requires the structure of the assembled complex, and may be effective against a variety of tumor systems.
Proinflammatory cytokine production following i.v. injection of LPD It has recently been observed that several cytokines with antitumor activity, namely TNF-␣, IFN-␥ and IL-12, are produced following tail vein injection of LPD in CD-1 mice. 5 It was hypothesized that these cytokines could be responsible for the antitumor effect observed with LPD. To determine whether cytokine production occurs in C57Bl/6 mice bearing 24JK-FBP pulmonary metastases, LPD formulated with 25 g of pCMV-Neo was injected into tumor-bearing mice 7 days following tumor inoculation. For these and all subsequent experiments, the empty plasmid pCMV-Neo was utilized to eliminate complicating immune responses that might result from the expression of a potentially antigenic transgene. Serum was collected at various times following injection and assessed for cytokine by ELISA (Figure 2 ). TNF-␣ and IL-12 could be detected as early as 2 h and at 6 h following injection. IFN-␥ was detected at 6 h and 12 h after injection and a relatively low level of IL-12 was observed at 12 h. Levels of TNF-␣ were greatest at 2 h, while levels of IFN-␥ and IL-12 peaked at 6 h. At 18 and 24 h all cytokine levels were minimal. In data not shown, there is no difference between cytokine response in tumor-free and tumor-bearing animals except that tumor-bearing mice showing visible signs of cachexia (ie near death) have an impaired ability to produce cytokine in response to LPD. These data demonstrate that C57Bl/6 mice bearing 24JK-FBP pulmonary metastases are capable of generating a rapid cytokine response to intravenous administration of LPD.
The cytokine profile observed with LPD is similar to an innate inflammatory response to bacterial DNA that is initiated by dendritic cells and macrophages with the rapid production of TNF-␣ and IL-12 and subsequent production of IFN-␥ from stimulated macrophages, NK cells and some T cell subsets. Because the plasmid DNA component of LPD is of bacterial origin, it was important to determine which component or combination of components was responsible for the observed cytokine response. C57BL/6 mice bearing 24JK-FBP metastases (7-9 days after inoculation) were treated with individual LPD components, combinations of components, and LPD with quantities that are consistent with an LPD complex containing 25 g of plasmid DNA (ie DOTAP: cholesterol liposomes -212.5 g DOTAP and protamine sulfate -15.0 g). At the time corresponding to peak response of the appropriate cytokine (2 h for TNF-␣ and 6 h for IFN-␥ and IL-12) serum was collected and assessed for cytokine ( Figure 3 ). When DNA was in complex with liposome, a cytokine response comparable with that observed with LPD was obtained. For the individual components and the liposome/protamine (LP) and protamine/DNA (PD) combination of components, there was no significant cytokine response compared with dextrose-treated controls. Thus, it is the combination of cationic liposome and plasmid DNA together in a lipoplex or in a lipopolyplex that provides the stimulus that results in cytokine production following i.v. injection. Figure 2 . Bars represent mean ± s.e.m. for between three and seven animals per group. Unmethylated CpG sequences in plasmid DNA are responsible for the antitumor activity of LPD Because CpG methylation inhibited the cytokine response to LPD it could be predicted that CpG methylation might also inhibit the antitumor activity of LPD. To test this, the experimental pulmonary metastasis model was treated as described in Figure 1 using LPD prepared with 25 g of either normal plasmid DNA (LPD) or methylated plasmid DNA (LPD-me) ( Figure 5 ). Methylation of CpG essentially abolished the antitumor effect of LPD (P Ͻ 0.001). Similarly, CpG methylation reversed growth inhibition of LPD on the C3 subcutaneous tumor model ( Figure 6 ). This demonstrates that unmethylated CpG motifs in plasmid DNA are responsible for the antitumor activity of LPD and, together with the cytokine data, suggest that proinflammatory cytokines mediate the antitumor activity of i.v. injected LPD.
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Systemic cytokine production following i.v. administration of LPD Biodistribution and gene expression studies with i.v. administration of LPD have demonstrated that the complex reaches several organs including the heart, liver, lung, kidney and spleen. Therefore, it was of interest to examine the production of cytokine in the various organs where LPD is distributed (Figure 7 ). Mice were injected with either dextrose (not shown) or a 25 g dose of LPD. At the peak time for serum cytokine levels (2 h for TNF-␣ and 6 h for IFN-␥ and IL-12) mice were killed. Serum and cytoplasmic fractions from the indicated organs were collected, as described in Materials and methods, and assessed for cytokine content by ELISA. Except for the heart, inflammatory cytokines were detected in the various organs where LPD distributes after i.v. administration. Among the organs tested, distribution of cytokine production was the same for all cytokines. The greatest levels were in the liver and spleen, with moderate levels in the kidney and lung, and almost no cytokine detected in the heart. In the heart, both IL-12 and IFN-␥ were not detected at levels above that associated with the blood fraction. The greatest levels of TNF-␣ were in the liver and spleen, while the greatest levels of IL-12 and IFN-␥ were in serum. In dextrose-treated animals (data not shown) cytokine levels in all organs except the liver were less than 3% of what was observed in LPD-treated mice (P Ͻ 0.01). For the liver, IL-12 in dextrose-treated mice was approximately 30% of that observed with LPD (P Ͻ 0.01), while TNF-␣ and IFN-␥ were less than 2% of LPD (P Ͻ 0.01). Moreover, CpG methylation significantly reduced (P Ͻ 0.01) cytokine levels in all organs where cytokine was detected (data not shown). Thus, elevated cytokine levels resulting from unmethylated CpG motifs in the plasmid component of LPD are observed in all organs where LPD is known to distribute.
i.v. LPD treatment does not inhibit the growth of 24JK-FBP pulmonary metastases in SCID mice
To determine whether the growth inhibitory activity of LPD on pulmonary metastases requires a full complement of B or T lymphocytes, the treatment of 24JK-FBP pulmonary metastases was assessed in SCID mice (ie mice deficient of B and T lymphocytes). On day 0, both C57BL/6 and SCID mice were injected i.v. with 0.5 × 10 6 24JK-FBP cells. Mice were treated with either dextrose or LPD containing 25 g pCMV-Neo and assessed for pulmonary metastasis (Figure 8 ) as described in Materials and methods. As expected, LPD treatment of C57Bl/6 mice inhibited the growth of pulmonary metastases by 87% (P = 0.017). In SCID mice, however, no inhibition of tumor growth was observed. In data not shown, the cytokine response to LPD in SCID mice was essentially identical to that oberved in C57BL/6 mice. Thus, for the antitumor activity of LPD, this indicates that the cytokines do not directly kill tumor cells and that maximal growth inhibition of pulmonary metastases requires either B or T lymphocytes as immune effector cells.
Discussion
In this report, the lipopolyplex developed in our laboratory consisting of DOTAP: cholesterol liposomes, protamine sulfate, and plasmid DNA (LPD) has been shown to possess a potent antitumor effect following intravenous administration for the treatment of experimental pulmonary metastasis (24JK-FBP) and subcutaneous (C3) models of tumor in C57BL/6 mice. The effect was observed independently of whether a therapeutic gene (hu-p53 or mIL-12) was encoded in the plasmid, was dose-dependent, required complex assembly, and did not result from contaminants which may be associated with LPD components (eg endotoxin from plasmid DNA). Although the level of inhibition was less than that observed with the experimental pulmonary metastasis model, efficacy against the subcutaneous model suggests that the antitumor activity is systemic in nature and may be applicable for a variety of tumor models. There are no clear data to demonstrate that LPD reaches the distant vasculature of subcutaneous tumors following i.v. administration (unpublished observations). The greater level of inhibition observed with the pulmonary metastasis model may reflect a need for localized uptake of LPD as well as local production of cytokine in order to obtain maximal efficacy.
Of the LPD components, only bacterial DNA, ie plasmid DNA, has been shown to possess antitumor activity. 8, 13 Indeed, a similar antitumor effect has been observed with subcutaneous and intraperitoneal tumor models following intra-tumor or intaperitoneal injection of bacterial DNA. 24, 25 Using these routes of administration, both free DNA and DNA in complex with cationic liposomes demonstrate an antitumor effect. In addition to its antitumor activity, bacterial DNA is also capable of stimulating a pro-inflammatory cytokine response 9, 10, 20, 23, 26 similar to the innate immune response to intracellular infection by bacteria and viruses. It appears that intracellular uptake of specific immunestimulatory CpG motifs are, in part, responsible for eliciting this response. 17 Macrophages and dendritic cells are stimulated by the intracellular uptake of bacterial DNA and CpG containing oligonucleotides (ODN) to produce IL-12 and TNF-␣. 10, 23 Lytic activity and IFN-␥ production in natural killer cells (NK) are enhanced by immunestimulatory sequences in bacterial DNA. 22, 23 In addition, bacterial DNA is directly mitogenic and can promote IL-6 production in B cells. 20, 21 All the activities have been implicated in anticancer immune responses and are likely to mediate the antitumor activity of bacterial DNA.
The observation that methylation of plasmid DNA at CpG blocked the antitumor effect of LPD strongly suggests that the plasmid DNA component of LPD is responsible for the antitumor effect. Moreover, a rapid and potent systemic production of TNF-␣, IFN-␥, and IL-12 is also observed following i.v. administration of LPD in tumor-bearing animals that is equivalent to that observed with tumor-free mice. The demonstration that methylation of CpG inhibited both cytokine production and antitumor activity suggests that the proinflammatory cytokine response mediates the antitumor activity of LPD. It is of interest that CpG methylation blocked TNF-␣ and IL-12 levels to near completion, while IFN-␥ levels were only partially inhibited. It is possible that one of the other components of LPD (L or P) stimulates IFN-␥ production by a mechanism that is not mediated by TNF-␣ or IL-12. On the other hand, it is also possible that since the methylation reaction is not 100% complete (ie estimated to be Ͼ95% by DNA agarose/ethidium bromide staining) the residual TNF-␣ and IL-12 which result from the remnant unmethylated CpG motifs are sufficient to stimulate an amplified IFN-␥ response. In either case, the residual cytokines are not sufficient to cause inhibition of tumor growth (see Figure 5) . It is not surprising that intravenous administration of free plasmid DNA had no antitumor activity, since DNA is short-lived in serum (t 1/2 Ͻ 4 min) resulting from a high nuclease activity. 27 It is well known that cationic liposomes as well as polycationic polymers can protect plasmid DNA from nuclease degradation, thereby increasing its serum half-life. Thus, the LPD complex may function to preserve the sequence(s) or structure(s) in plasmid DNA that are responsible for eliciting the antitumor activity. Another possibility is that packaging of plasmid DNA in combination with cationic liposome is required for optimal uptake by cells that are capable of initiating the cytokine response to unmethylated CpG motifs. This could explain the lack of cytokine response observed not only with free plasmid DNA, but also with plasmid in complex with protamine which is more stable in serum. In contrast to our observation with i.v. administration of naked plasmid DNA, Cowdery and colleagues 28 demonstrated that i.v. administration of 300 g of naked E. coli DNA enhanced the systemic production of TNF-␣, IFN-␥ and IL-6 in response to LPS challenge. The difference in observations could be explained by the difference in dose (E. coli DNA was greater than 10× the dose of naked plasmid DNA tested here) and the size of the E. coli genomic DNA. For example, at that dose large genomic DNA may not be sufficiently degraded by serum nuclease activity to destroy the immune-stimulatory motifs. Thus, the undigested immune-stimulatory fragments that remain following i.v. administration of E. coli DNA may be capable of initiating the cytokine response.
Because the cytokine response to LPD remains viable in SCID mice, while the antitumor activity is lost ( Figure  8 ), a direct action of cytokines on tumor cell killing is not likely. Thus, it appears that either B or T lymphocytes play an essential role in the antitumor response since mice deficient of these cells (ie SCID mice) were unable to mount an effective antitumor response associated with LPD injection. It should be noted that the lack of an antitumor effect in SCID mice does not preclude a role for NK or LAK cells in the growth inhibitory effect of LPD even though these cells are present in SCID animals. It is conceivable that NK or LAKs are activated to initiate tumor killing which ulitmately results in specific and more efficient killing by immune effectors such as B and T cells in immune-competent mice. Clearly, additional work is required to identify the immunological players involved with the antitumor activity of LPD.
In contrast to our findings, two recent reports have demonstrated gene-specific efficacy in treating murine models of pulmonary metastasis by i.v. administration of cationic liposome-based vectors. 29, 30 In one system, Rb gene delivery using LPD inhibited the growth of pulmonary metastases that spontaneously develop in Rb +/− mice. 29 In the other study, cationic liposome-DNA complex gene delivery of GM-CSF, angiostatin and p53 inhibited the growth of the experimental pulmonary metastasis model of B16-F 10 melanoma in C57BL/6 mice. 30 In both cases, complexes containing noncoding control plasmid exhibited no tumor growth inhibition. This is not surprising since both studies utilized tumor models that are likely to be at most minimally immunogenic. For example, tumors that develop in the Rb +/− mice grow slowly and develop over the course of 1 year in immunecompetent animals, and therefore are likely to be minimally immunogenic. The B16-F 10 tumors are known to be non-immunogenic because they lack detectable class I MHC expression. 31, 32 Therefore, one might predict that tumors that are minimally immunogenic would be less susceptible to the Th1-like cytokine response elicited by cationic liposome-based vectors. In contrast, the tumor models utilized in this study are at least mildly immunogenic (24JK-FBP) or known to be highly immunogenic (C3). 33, 34, 35 Although the 24JK-FBP line was derived by retroviral transfection of human folate-binding protein into the lowly immunogenic 24JK parental line, 36 the immunogenicity of the resultant 24JK-FBP line is not known. However, the immunogenicity of 24JK-FBP is almost certain to be increased, compared with the parental line, due to stable integration of the retroviral genes and human FBP. Thus, it appears that tumors that are moderately or highly immunogenic are susceptible to the cytokine-mediated antitumor effects of the cationic liposome-based LPD, while tumors classified as lowly immunogenic or non-immunogenic are resistant. Moreover, the tumors utilized here appear so susceptible to the cytokine response that any gene-specific killing was masked by this strong cytokine response. On the other hand, what is not clear is the role of vector-associated cytokine production with the gene-specific antitumor effects noted against the tumors of Rb +/− mice and the B16-F 10 melanomas. It is possible that the gene-specific killing observed in these systems was augmented by the cytokine response to the cationic liposome vector that further elicited an effective tumor-specific immune response. At worst, the cytokine-mediated immune response to i.v. injection of LPD represents an effective means to inhibit the growth of immunogenic and metastatic tumors. In addition, with any gene therapy regimen where tumor growth inhibition is assessed, one must carefully control for antitumor effects associated with the cytokine response to DNA and growth inhibition associated with expression of the specific gene of interest. Appropriate DNA (viral or nonviral) controls for immune stimulation should have the same quantity of is-DNA motifs, but not express the therapeutic gene of interest. For example, disruption of the translation start signal (by mutation or deletion) could achieve these criteria assuming the disruption does not alter neighboring is-motifs.
With the identification of tumor-associated antigens (TAA) and the subsequent advancement for the field of cancer immunotherapy, 37 cytokine therapies for the treatment of cancer appear to demonstrate promise either by themselves or as adjuvants to TAA therapies. [38] [39] [40] While varying degrees of innate inflammatory responses are mounted against nonviral and viral vectors, a specific immune response is generated against viral vectors due to a greater level of antigenicity. 41 This acquired response reduces the efficacy of repetitive administration of viral vectors. An advantage that cationic liposome-based lipoplexes possess over viral vectors is that they are less antigenic and therefore suitable for strategies requiring repeated injections 5, 6, 42 such as TAA therapy. Therefore, cationic liposome-based vectors or LPD might be effective in providing repeated boosts for specific tumor antigens since immunity would be raised against cells producing antigen, but not against the vector itself. Thus, i.v. administration of LPD could play a dual role as an effective immune adjuvant and as a delivery vehicle for genes encoding tumor-associated antigens to antigen presenting cells in vivo. While the cytokine response elicited by LPD may represent an effective cytokine therapy for cancer, toxicity issues need to be addressed when designing such strategies. Clearly the TNF-␣ levels observed following LPD injection approach those which are observed with toxic shock syndrome. [43] [44] [45] Indeed, a future challenge is to harness the antitumor activity of LPD to direct specific immunity against certain types of cancer. 
Materials and methods
Preparation of LPD and LPD components
Small unilamellar cationic liposomes consisting of a 1:1 molar ratio of DOTAP: cholesterol were prepared in 5.2% dextrose (for isotonic i.v. injection) by the method of thinfilm hydration followed by extrusion 46 to a mean diameter of 150 nm by particle size analysis. Plasmid DNA was propagated in DH5␣ strain of E. coli under selective growth conditions with the appropriate antibiotic. Plamid was isolated from bacteria by alkaline lysis followed by column chromatography using either size exclusion according to the method of Sorgi (pEGFP-N1 and pCMV-IL-12) or Ion exchange according to the Endofree Plamid Kits from Qiagen, Valencia, CA, USA (pCMV-Neo and pCMV-p53). LPS contamination was determined for plasmid preparations using the Quantitative Chromogenic Lymulus Amebocyte Assay (QCL-1000) from BioWhittaker, Walkersville, MD, USA. LPS was removed from plasmid preparations that tested positive using the Endofree Plasmid Kit from Qiagen. DNA methylated at CpG was prepared by enzymatic methylation of pCMV-Neo with SSI methylase (New England Biolabs, Beverly, MA, USA) which methylates CpG sequences at carbon position 5 of cytosine. The methylation reaction was incubated for at least 2 h at 37°C and contained 2 U methylase/g DNA. Methylation was detemined to be Ն95% by a BstU I endonuclease protection assay visualized on an ethiduim bromide-stained DNA agarose electrophoresis gel. The pCMV-p53 plasmid produced functional protein as assessed in vivo following LPD i.v. delivery to lung tumors by immunohistochemistry. Expression was also demonstrated in vitro using transfection experiments followed by detection with either a Western blot or the activity of a reporter gene where reporter expression is controlled by a p53 response element in the promotor. The pCMV-IL-12 plasmid encodes for murine IL-12 and tested positive for expression of functional protein in vitro using a murine IL-12 p70 ELISA of cell culture supernatants following transfection.
The LPD ternary complex was prepared in 5.2% dextrose as described by Li and colleagues 4 with an 8.5:0.6:1.0 weight ratio (g) of DOTAP:protamine sulfate:DNA. The theoretical charge ratio (+/−) of the complex is 4. Equal volume solutions of plasmid DNA and DOTAP liposome/protamine sulfate were prepared in 5.2% dextrose. The plasmid DNA solution was slowly added to the liposome/protamine solution by dropwise addition with continuous mixing. The resulting ternary lipopolyplex was incubated at room temperature for at least 20 min before injection. Dosing of animals was based on the plasmid DNA content in the lipopolyplex and consisted of 25.0, 12.5 and 6.25 g plasmid DNA per mouse in a volume of 300 l. The lower concentrations of complex were prepared by doubling dilution of the concentrated complex in 5.2% dextrose. The LPD complexes were either immediately injected or stored at 4°C for up to 3 weeks. LPD components were prepared based on the quantities contained in a 25.0 g dose of LPD. For individual components 212.5 g of DOTAP in DOTAP cholesterol liposomes (L), 15.0 g of protamine sulfate (P), or 25.0 g of pCMV-neo (D) was prepared in a final volume of 300 l of 5.2% dextrose. For the liposome/protamine sulfate (LP) combination of components, the appropriate quantities of DOTAP liposomes and protamine sulfate were prepared in a final volume of 300 l of 5.2% dextrose. For the liposome/DNA (LD) and protamine/DNA (PD) combinations, equal volumes of DNA solution and either liposome or protamine solutions were mixed by dropwise addition with continuous mixing up to a final volume of 300 l. The components were prepared immediately before injection.
Tumor models
Experimental pulmonary metastasis: The 24JK-FBP tumor cells used for the experimental pulmonary metastasis model were kindly provided by the laboratory of Dr Patrick Hwu (National Cancer Institute, Bethesda, MD, USA). These cells, which were retrovirally transduced to express human folate binding protein, 36 were derived from the 24JK clone 47 isolated from the 3-methylcholanthrine-induced, poorly immunogenic MCA 102 murine sarcoma. 48 Cells were grown as a monolayer in medium consisting of RPMI supplemented with 10% FBS and penicillin/streptomycin antibiotics (Gibco BRL, Rockville, MD, USA). The cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 . In preparation for injection, cells were collected by trypsinization, washed three times in serum-free RPMI, and resuspended in warm (37°C) cell dissociation medium (Sigma) at a density of 3.33 × 10 6 /ml. On day 0, female C57Bl/6 mice (6-8 weeks) were injected by tail vein with 1 × 10 6 tumor cells in a volume of 300 l. In experiments comparing tumor growth in C57BL/6 and SCID mice, animals were injected with 0.5 × 10 6 cells.
Subcutaneous model of C3 fibrosarcoma:
The C3 fibrosarcomma cells were kindly provided by Dr Yukai He from our laboratory. These cells represent a highly immunogenic, murine tumor model of cervical cancer that are positive for the human papilloma virus 16 genome. The cells were grown in tissue culture and prepared for inoculation as described above, except that cells were resuspended in Hanks buffer (Gibco) for inoculation instead of cell-dissociation medium. On day 0, mice were inoculated with a subcutaneous injection of 0.5 × 10 6 C3 cells in a volume of 50 l on the ventral side of the mouse above the abdomen. On day 3 following C3 inoculation, palpable tumors were observed on all mice and treatment was initiated.
Animal treatments
Within the first week (3-7 days) following tumor inoculation, mice were injected intravenously by tail vein with 5.2% dextrose, the indicated LPD component(s), or LPD containing the indicated quantities of various plasmids. For tumor burden experiments, mice received two subsequent injections spaced at 10 day intervals following the first injection.
Tumor burden assays
India ink assay for pulmonary metastasis: When mice demonstrated visible signs of cachexia (ie weight loss, piloerection and decreased mobility) they were killed by cervical dislocation. When all the dextrose control animals had been killed, the remaining animals were killed regardless of their conditions of health. Immediately following death, animals were assessed for pulmonary metastatic tumor burden by the India ink assay. 49 Tumors were visualized and counted under a dissecting microscope. Due to variance in tumor number between experiments, tumor burden was normalized to % average dextrose control for each experiment as follows: [(No. of pulmonary metastases in mouse)/(average No. of metastases in dextrose control)] × 100. Between experiments, the average number of lung metastases observed in dextrose control groups ranged from 231 to 423 tumors/mouse (n = 39).
Caliper measurement of subcutaneous tumors: Throughout the treatment schedule, subcutaneous tumors were periodically measured in two dimensions by caliper measurement. Due to variance in the rate of tumor growth between experiments, tumor size was normalized to the average size of tumors in dextrose-treated animals at the endpoint (30-32) of each experiment (including individual tumors in the dextrose treatment group). The calculation for tumor size which is represented as % average dextrose control was as follows: [(tumor size of measured tumor in mm 2 )/(average tumor size of dextrose controls in mm
2 )] × 100.
Cytokine determinations
Serum and organ cytokine levels were determined by ELISA for murine TNF-␣, murine IL-12 p70 (for detection of active heterodulpex) and murine IFN-␥. Blood was collected from mice by retro-orbital bleeding at the indicated time following injection of dextrose, LPD component(s), or LPD. Blood was allowed to coagulate for 2-3 h at 4°C and serum was isolated as the supernatant fraction following centrifugation at 6000 g for 10 min. Serum samples were immediately stored at −80°C until time of ELISA. Organs were collected following retro-orbital bleeding, washed five times in ice-cold saline, blotted dry and stored at −80°C until time of ELISA. At the time of ELISA, organs were slowly thawed on ice. The organs were then homogenized in 1 ml of PBS containing a cocktail of protease inhibitors (aprotinin -2.0 g/ml, leupeptin -2.0 g/ml, Pepstatin A -1.0 g/ml, and PMSF -100.0 g/ml) using a tissue tearing homogenizer. The cytoplasmic fraction was isolated as the supernatant fraction following centrifugation at 15 000 g for 10 min at 4°C. This fraction was immediately assessed for cytokine by ELISA following the manufacturer's instructions. Cytokine levels associated with blood contamination of the organs was subtracted to give 'total cytokine' values.
Statistical analysis
All the indicated statistical analyses were performed using GraphPad Prism software from GraphPad Prism.
